RxDoctor Payments Data

Ayesha Hameed

Interventional Pain Medicine · Farmingdale, NYNPI 1801200423

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Medtronic at 26.5% of the total. Reporting peaked in 2021 at $990 and has fallen 61.0% since, to $387 in 2025.

$4,467in general payments, 2019–2025

Across 89 payments — averaging $50.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Abbott$532
  • SPR Therapeutics, Inc$515
  • Boston Scientific$505
  • Novo Nordisk$500
  • Relievant Medsystems, Inc.$201
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,467100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,467 in reported general payments places this provider in the 55th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$663,385
Medicare patients
809
Services billed
16,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pregabalin112$5,156
Lidocaine65$3,366
Tizanidine Hcl462$3,078
Gabapentin406$2,343
Meloxicam351$1,206
Cyclobenzaprine Hcl61$775
Duloxetine Hcl71$699
Diclofenac Sodium75$674
Oxycodone Hcl41$671
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen38$642
Methylprednisolone91$641
Celecoxib34$546
Tramadol Hcl67$256
Acetaminophen-CodeineAcetaminophen With Codeine26$219
Methocarbamol26$183

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Farmingdale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →